Oral Presentation Australia and New Zealand Society for Extracellular Vesicles Conference 2023

Messengers in the microenvironment: the role of extracellular vesicles in fat graft retention (#25)

Emma Symonds 1 , Rachelle Smith 1 , Alexander Brown 2 , Margaret Currie 3 , Elizabeth Dennett 1 , Ineke Meredith 4 , Kathryn Hally 1 , Kirsty Danielson 1
  1. Department of Surgery and Anaesthesia, University of Otago, Wellington, New Zealand
  2. Department of Surgery, Wellington Regional Hospital, Wellington, New Zealand
  3. Mackenzie Cancer Research Group, University of Otago, Christchurch, New Zealand
  4. Department of General Surgery, Wakefield Hospital, Wellington, New Zealand

Background: Autologous fat grafting (AFG) is a favourable surgical option for oncologic breast reconstruction post breast cancer surgery; however, retention rates are variable, limiting AFGs clinical utility. Low graft retention is largely due to a failure of the graft to integrate into the recipient site. Extracellular vesicles (EVs) released by adipose-derived stem cells (ADSCs) could be used as an acellular therapeutic for enhancing AFG retention by promoting angiogenesis and stimulating a favourable inflammatory and fibrotic state.

Methods: Lipoaspirates were collected from patients undergoing AFG and ADSCs were isolated enzymatically and cultured. ADSC-EVs were isolated from culture media by SEC and characterised by TRPS, Western blot, and TEM. ADSC-EVs were added to single-cell cultures of human monocyte-derived-macrophages (MDMs), HUVECs, and fibroblasts. 3D multicellular models were created to mimic the breast microenvironment and further assess the functional role of ADSC-EVs. Models were imaged using fluorescent confocal microscopy.

Results: ADSC-EV replicates from three donors significantly reduced the expression of markers associated with antigen presentation, adhesion, and scavenging on MDMs and high dimensional analysis of a 10-marker panel demonstrated a reduction in expression of inflammatory clusters across all MDM phenotypes. ADSC-EVs also increased fibroblast proliferation under unstimulated (1.14-fold, p=0.0009) and pro-inflammatory (1.15-fold, p=0.0006) conditions, but decreased proliferation under pro-fibrotic conditions (0.84-fold, p=0.0002). In multicellular models, ADSC-EVs consistently increased tube formation in HUVECs (2.60-fold, p<0.0001) and increased co-localization of MDMs and HUVECs (1.21-fold, p=0.0246).

Conclusions: ADSC-EVs have pro-angiogenic and anti-inflammatory effects, indicating that ADSC-EVs may be an appropriate therapeutic in the context of AFG.